-
AVLN share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Price change
The price of AVLN shares has increased $0.44 since the market last closed. This is a 1.57% rise.
-
Opened at $27.90.
The stock opened $0.20 lower than its previous close.
Key terms
About AVLN
Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.
-
Market cap: $1.25B
A market capitalization between $300 million and $2 billion places AVLN in the small capitalization category.
Key terms
Smart score
Latest AVLN news
AVLN Financials
-
AVLN total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
AVLN net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
AVLN earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Key terms
AVLN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AVLN Competitors
-
How competitors are chosen
AVLN's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $1.25B
A market capitalization between $300 million and $2 billion places AVLN in the small capitalization category.
